
Yingkai Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6711445/publications.pdf Version: 2024-02-01



VINCEALLI

#	Article	IF	CITATIONS
1	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
2	Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. Frontiers in Neurology, 2018, 9, 77.	2.4	34
3	Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental Neurology, 2019, 312, 43-50.	4.1	23
4	Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. Journal of Neuroimmunology, 2020, 345, 577279.	2.3	17
5	Knowledge and perceptions of the <scp>COVID</scp> â€19 pandemic among patients with myasthenia gravis. Muscle and Nerve, 2021, 63, 357-364.	2.2	13
6	Normative dataset for plasma cytokines in healthy human adults. Data in Brief, 2021, 35, 106857.	1.0	11
7	The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal of Neuroimmunology, 2022, 367, 577850.	2.3	9
8	Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clinical Immunology, 2020, 218, 108492.	3.2	7
9	Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis. Clinical Immunology, 2019, 205, 130-137.	3.2	5
10	Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clinical Immunology, 2021, 231, 108830.	3.2	4